Vaccine Composition

The Influenza Vaccine Formulation process:

In February (for the NH) and September (for SH) WHO convenes a consultation involving the five major influenza centres (one here in Australia), three major regulatory authorities (including Australia’s TGA) and other experts, to review all of the available information on influenza, epidemiological, antigenic and genetic at that time and to recommend the most appropriate formulation for the coming season’s vaccine. This often results in at least one of the four component strains being updated since the previous six monthly meeting.

Shortly after the WHO recommendations regarding vaccine formulation are made (2019 WHO SH recommendations) regional or national committees are convened to ratify the recommendation as relevant to their jurisdiction. Consideration is given to laboratory reference strains, with viruses that have been derived in a way acceptable to regulatory agencies (ie viruses with a ‘clean’ pedigree and the antigenic characteristic of the reference strains). Requirements for laboratory reference reagents necessary for vaccine standardisation and quality control are also set at that time. Where new strains are incorporated into the formulation it is necessary to then improve their growth characteristics, in an approved laboratory, so that they will meet manufacturers’ requirements and for regulatory authorities to prepare the reference reagents. Once they receive the strains the manufacturers then need to fine-tune their production processes to reach adequate yields – different viruses can have different growth characteristics and processing requirements. These are all time-consuming activities, particularly when the formulation involves new strains.

Influenza Vaccine Composition 2019 - Southern Hemisphere/Australia

The formulation of influenza vaccines for use in Australia is determined each year by the Australian Influenza Vaccine Committee (AIVC) based on information and recommendations from the World Health Organization (WHO).  A meeting of the AIVC was held on 10th October 2018 where the expert committee reviewed and evaluated data related to epidemiology, antigenic and genetic characteristics of recent influenza isolates circulating in Australia and the Southern Hemisphere, serological responses to 2017-2018 vaccines, and the availability of candidate vaccines viruses and reagents. The committee recommended that the TGA should adopt the 27 September 2018 WHO recommendations; the influenza vaccine components for the Australian 2019 influenza season should contain the following:

The influenza vaccine for the Australian 2019 influenza season is to contain the following virus strains:

Egg based Quadrivalent influenza:

  • an A/Michigan/45/2015 (H1N1)pdm09-like virus;
  • an A/Switzerland/8060/2017 (H3N2)-like virus;
  • a B/Colorado/06/2017-like virus (B/Victoria/2/87 lineage); and
  • a B/Phuket/3073/2013-like virus (B/Yamagata/16/88 lineage)

Egg based Trivalent vaccines:

  • an A/Michigan/45/2015 (H1N1)pdm09-like virus;
  • an A/Switzerland/8060/2017 (H3N2)-like virus; and
  • a B/Phuket/3073/2013-like (B/Yamagata/16/88 lineage)

Non-egg based vaccines:

  • A(H3N2) component: A/Singapore/INFMH-16-0019/2016 (H3N2)-like virus

Other components the same as above indicated for egg based vaccines

1.     WHO 2019 Southern Hemisphere recommendation 

2.    TGA / AIVC Recommendations

Influenza Vaccine Composition 2018/19 - Northern Hemisphere

The World Health Organisation (WHO) has announced its recommended formulation for influenza vaccines to be used in the Northern Hemisphere winter 2018-19. This follows  a  3-day WHO Consultation with Advisers from WHO CCs and WHO ERLs based on year-round surveillance by the WHO Global Influenza Surveillance and Response System (GISRS).

It is recommended that trivalent vaccines for use in the 2018-2019 northern hemisphere influenza season contain the following:

  • an A/Michigan/45/2015 (H1N1)pdm09-like virus;
  • an A/Singapore/INFIMH-16-0019/2016 (H3N2)-like virus;
  • a B/Colorado/06/2017-like virus (B/Victoria/2/87 lineage); and
  • a B/Phuket/3073/2013-like virus (B/Yamagata/16/88 lineage).

It is recommended that the influenza B virus component of trivalent vaccines for use in the 2018-2019 northern hemisphere influenza season be a B/Colorado/06/2017-like virus of the B/Victoria/2/87-lineage.

Available candidate vaccine viruses following the above recommendation and the full technical reports can be found at:

In addition, the review on vaccine viruses for zoonotic influenza vaccine development is updated through the WHO Consultation:

The availability of candidate vaccine viruses of seasonal influenza vaccines, and of other subtypes of influenza for pandemic preparedness purposes can be found at:

Last updated:  15 October 2018